Cargando…

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction

BACKGROUND: This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric junction. METHODS: Patients received neoadjuva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moehler, Markus, Gockel, Ines, Roessler, Hans-Peter, Arnold, Dirk, Trarbach, Tanja, Thomaidis, Thomas, Klautke, Gunther, Rödel, Claus, Brenner, Baruch, Lang, Hauke, Galle, Peter R, Schimanski, Carl C, Schmidberger, Heinz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579685/ https://www.ncbi.nlm.nih.gov/pubmed/23394629 http://dx.doi.org/10.1186/1471-2407-13-75

Ejemplares similares

Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications
por: Schiffmann, Leif, et al.
Publicado: (2013)

Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control study
por: Sgourakis, George, et al.
Publicado: (2012)

Prognosis of rectal cancer patients improves with downstaging by intensified neoadjuvant radiochemotherapy - a matched pair analysis
por: Schiffmann, Leif, et al.
Publicado: (2013)

Loss of LLGL1 Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases
por: Desuki, Alexander, et al.
Publicado: (2019)

Dose-escalated neoadjuvant chemoradiotherapy for locally advanced oesophageal or oesophagogastric junctional adenocarcinoma
por: Duque-Santana, Victor, et al.
Publicado: (2022)

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
por: Tebbutt, N C, et al.
Publicado: (2013)

Phase 2 trial of neoadjuvant docetaxel, oxaliplatin, and S‐1 for clinical stage III gastric or esophagogastric junction adenocarcinoma
por: Kurokawa, Yukinori, et al.
Publicado: (2022)

Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer
por: Dellas, Kathrin, et al.
Publicado: (2013)

Laparoscopic fundoplication and new aspects of neural anatomy at the oesophagogastric junction
por: Gehwolf, P., et al.
Publicado: (2020)

Strong Expression of Chemokine Receptor CXCR4 by Renal Cell Carcinoma Correlates with Advanced Disease
por: Wehler, Thomas C., et al.
Publicado: (2008)

Docetaxel as Salvage Therapy in Highly Pretreated and Drug Resistant Gastrointestinal Carcinomas
por: Sprinzl, Martin F., et al.
Publicado: (2008)

Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study
por: Du, Rongxu, et al.
Publicado: (2022)

Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas
por: Schmidt, T, et al.
Publicado: (2014)

Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial
por: Tebbutt, Niall C, et al.
Publicado: (2016)

Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, L, et al.
Publicado: (2007)

Predictive Factors of the Response of Rectal Cancer to Neoadjuvant Radiochemotherapy
por: Spolverato, Gaya, et al.
Publicado: (2011)

ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)
por: Reynolds, JV, et al.
Publicado: (2017)

VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
por: Thomaidis, Thomas, et al.
Publicado: (2014)

Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma
por: Gockel, Ines, et al.
Publicado: (2006)

The impact of chemosensory and food-related changes in patients with advanced oesophagogastric cancer treated with capecitabine and oxaliplatin: a qualitative study
por: de Vries, Yfke C., et al.
Publicado: (2016)

Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft—no benefit of combination therapy
por: Wehler, Thomas C., et al.
Publicado: (2012)

Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report
por: Sprinzl, Martin F, et al.
Publicado: (2006)

Perioperative Safety and Effectiveness of Neoadjuvant Therapy with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Plus Apatinib in Locally Advanced Gastric Cancer
por: Zhang, Yonglei, et al.
Publicado: (2021)

Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma
por: Noble, F, et al.
Publicado: (2017)

Identification of potential metabolic biomarkers of rectal cancer and of the effect of neoadjuvant radiochemotherapy
por: Rodríguez-Tomàs, Elisabet, et al.
Publicado: (2021)

Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2)
por: Rades, Dirk, et al.
Publicado: (2020)

Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study
por: Basso, Valeria, et al.
Publicado: (2019)

Oxaliplatin‐ and docetaxel‐induced polyneuropathy: clinical and neurophysiological characteristics
por: Bennedsgaard, Kristine, et al.
Publicado: (2020)

Neoadjuvant Intraperitoneal and Systemic Chemotherapy Versus Neoadjuvant Systemic Chemotherapy With Docetaxel, Oxaliplatin, and S-1 for Gastric Cancer With Peritoneal Metastasis: A Propensity Score Matched Analysis
por: Zhang, Xin, et al.
Publicado: (2021)

Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, Luigi, et al.
Publicado: (2009)

Erratum to: Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective
por: Wehler, Thomas C., et al.
Publicado: (2013)

Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective
por: Wehler, Thomas C., et al.
Publicado: (2013)

Radiochemotherapy
Publicado: (1998)

Prognostic value of the micronucleus assay for clinical endpoints in neoadjuvant radiochemotherapy for rectal cancer
por: Dröge, Leif Hendrik, et al.
Publicado: (2021)

The role of neoadjuvant radiochemotherapy in the management of localized high-grade soft tissue sarcoma
por: Kobus, Marta, et al.
Publicado: (2022)

Neoadjuvant versus definitive radiochemotherapy of locoregionally advanced oesophageal cancer—who benefits?
por: Schiffner, Christoph, et al.
Publicado: (2022)

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
por: Tebbutt, N C, et al.
Publicado: (2010)

Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4
por: Schimanski, C C, et al.
Publicado: (2006)

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
por: Heinrich, Stefan, et al.
Publicado: (2011)

Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis
por: Zhang, Xin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d7tuc0qppuj0m8q9c7k03sq0oq